Phase I Study of Concurrent Weekly Docetaxel and Repeated Samarium-153 Lexidronam in Patients With Castration-Resistant Metastatic Prostate Cancer

PURPOSE: Samarium-153 ((153)Sm) lexidronam is a bone-targeting radiopharmaceutical with a short physical half-life and a favorable toxicity profile. We evaluated the safety and feasibility of a concurrent combination of weekly docetaxel with repeated (153)Sm-lexidronam in patients with castration-re...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Clin Oncol
Prif Awduron: Tu, Shi-Ming, Mathew, Paul, Wong, Franklin C., Jones, Donnah, Johnson, Marcella M., Logothetis, Christopher J.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Clinical Oncology 2009
Pynciau:
ORIGINAL REPORTS
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4371137/
https://ncbi.nlm.nih.gov/pubmed/19414670
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.20.5393
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg